Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/3072% below fair value
$5.89−0.15 (-2.48%)
Close on Nov 12, 2026Market cap $302.00MP/E –Yield –
Emergent BioSolutions r&d expenses
Research and development expenses are spending on new products and technology.
Emergent BioSolutions's R&D Expenses for the twelve months ending Sep 30, 2026 was $41.20M, down 17.9% year over year. For fiscal 2025 it was $53.20M, down 24.8% from the year before. Over ten years it grew -7.7% a year on average. The highest annual figure on record is $237.90M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.20M | -24.8% |
| FY2024 | Dec 31, 2024 | $70.70M | -36.5% |
| FY2023 | Dec 31, 2023 | $111.40M | -40.8% |
| FY2022 | Dec 31, 2022 | $188.30M | -19.9% |
| FY2021 | Dec 31, 2021 | $235.20M | -1.1% |
| FY2020 | Dec 31, 2020 | $237.90M | +5.2% |
| FY2019 | Dec 31, 2019 | $226.20M | +58.4% |
| FY2018 | Dec 31, 2018 | $142.80M | +46.6% |
| FY2017 | Dec 31, 2017 | $97.40M | -8.9% |
| FY2016 | Dec 31, 2016 | $106.90M | -10.3% |
| FY2015 | Dec 31, 2015 | $119.19M | +13.8% |
| FY2014 | Dec 31, 2014 | $104.72M | -12.7% |
| FY2013 | Dec 31, 2013 | $119.93M | -0.2% |
| FY2012 | Dec 31, 2012 | $120.23M | -3.7% |
| FY2011 | Dec 31, 2011 | $124.83M | +39.8% |
| FY2010 | Dec 31, 2010 | $89.30M | +19.7% |
| FY2009 | Dec 31, 2009 | $74.59M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $9.40M | -30.4% |
| Q2 FY2026 | Jun 30, 2026 | $9.20M | -26.4% |
| Q1 FY2026 | Mar 31, 2026 | $10.50M | -30.5% |
| Q4 FY2025 | Dec 31, 2025 | $12.10M | +33.0% |
| Q3 FY2025 | Sep 30, 2025 | $13.50M | -2.2% |
| Q2 FY2025 | Jun 30, 2025 | $12.50M | -61.8% |
| Q1 FY2025 | Mar 31, 2025 | $15.10M | 0.0% |
| Q4 FY2024 | Dec 31, 2024 | $9.10M | -69.0% |
| Q3 FY2024 | Sep 30, 2024 | $13.80M | -9.8% |
| Q2 FY2024 | Jun 30, 2024 | $32.70M | +25.8% |
| Q1 FY2024 | Mar 31, 2024 | $15.10M | -62.9% |
| Q4 FY2023 | Dec 31, 2023 | $29.40M | -37.4% |
| Q3 FY2023 | Sep 30, 2023 | $15.30M | -63.7% |
| Q2 FY2023 | Jun 30, 2023 | $26.00M | -47.8% |
| Q1 FY2023 | Mar 31, 2023 | $40.70M | -12.3% |
| Q4 FY2022 | Dec 31, 2022 | $47.00M | -44.2% |
| Q3 FY2022 | Sep 30, 2022 | $42.20M | -14.9% |
| Q2 FY2022 | Jun 30, 2022 | $49.80M | +1.8% |
| Q1 FY2022 | Mar 31, 2022 | $46.40M | -11.6% |
| Q4 FY2021 | Dec 31, 2021 | $84.20M | +33.9% |
| Q3 FY2021 | Sep 30, 2021 | $49.60M | -41.2% |
| Q2 FY2021 | Jun 30, 2021 | $48.90M | +2.1% |
| Q1 FY2021 | Mar 31, 2021 | $52.50M | +23.0% |
| Q4 FY2020 | Dec 31, 2020 | $62.90M | +0.2% |
| Q3 FY2020 | Sep 30, 2020 | $84.40M | +58.1% |
| Q2 FY2020 | Jun 30, 2020 | $47.90M | -25.0% |
| Q1 FY2020 | Mar 31, 2020 | $42.70M | -7.4% |
| Q4 FY2019 | Dec 31, 2019 | $62.80M | +20.8% |
| Q3 FY2019 | Sep 30, 2019 | $53.40M | +44.3% |
| Q2 FY2019 | Jun 30, 2019 | $63.90M | +158.7% |
| Q1 FY2019 | Mar 31, 2019 | $46.10M | +58.4% |
| Q4 FY2018 | Dec 31, 2018 | $52.00M | +82.4% |
| Q3 FY2018 | Sep 30, 2018 | $37.00M | +63.3% |
| Q2 FY2018 | Jun 30, 2018 | $24.70M | -4.1% |
| Q1 FY2018 | Mar 31, 2018 | $29.10M | +42.1% |
| Q4 FY2017 | Dec 31, 2017 | $28.51M | +10.8% |
| Q3 FY2017 | Sep 30, 2017 | $22.66M | – |
| Q2 FY2017 | Jun 30, 2017 | $25.75M | – |
| Q1 FY2017 | Mar 31, 2017 | $20.48M | – |
| Q4 FY2016 | Dec 31, 2016 | $25.73M | – |
See a number that looks wrong?